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1. Introduction
Basic and applied cancer research has historically relied on var-
ious in vitro cell-based models to investigate signaling pathways 
and mechanisms underlying different phenotypes and func-
tions of cancer cells including metabolism, growth, migration, 
matrix invasion, and drug resistance.[1,2] Additionally, cancer 
drug discovery efforts in academia and pharmaceutical indus-
tries have long benefited from cell-based disease models to 
evaluate toxicity profiles and biological activities of compounds 
against cancer cells, mechanisms of drug effects, and off-target 
interactions.[3,4] Importantly, the adaptability of cell-based 
models to miniaturized culture platforms enables automated, 
Evolving understanding of structural and biological complexity of tumors has 
stimulated development of physiologically relevant tumor models for cancer 
research and drug discovery. A major motivation for developing new tumor 
models is to recreate the 3D environment of tumors and context-mediated 
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of standard monolayer cancer cell cultures. Under defined culture condi-
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Additionally, cancer cells may recapitulate steps in embryonic development 
to self-organize into 3D cultures known as organoids. Importantly, spheroids 
and organoids reproduce morphology and biologic properties of tumors, 
providing valuable new tools for research, drug discovery, and precision 
medicine in cancer. This Progress Report discusses uses of both natural and 
synthetic biomaterials to culture cancer cells as spheroids or organoids, spe-
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key properties of native tumors. The report concludes with the perspectives 
on the utility of these models and areas of need for future developments to 
more closely mimic pathologic events in tumors.
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high throughput screening of libraries of 
chemical compounds to expedite identifi-
cation of lead compounds for subsequent 
tests in animal models and clinical trials.
Monolayer cultures of adherent cancer 
cells have traditionally been used for these 
applications.[5] The ease of forming and 
maintaining 2D cultures of cells and their 
compatibility with various culture vessels 
and a broad range of biochemical assays 
have made 2D cultures indispensable to 
cancer research.[6] Despite these benefits, 
evolving understanding of the complexity 
of cancer clearly establishes that 2D cul-
tures fail to recapitulate pathophysiolog-
ical features of human tumors. Adhesion 
of cells to nonphysiologic stiff substrates 
such as plastic and glass, lack of a com-
pact morphology and close cell–cell and 
cell–matrix contacts, exposure of cells to 
an environment of uniform nutrients and 
oxygen content, and absence of matrix 
proteins all are major shortcomings of 
2D cancer cell cultures. Although 2D models allow cocultures 
of cancer and stromal cells to study heterotypic cellular inter-
actions, disparities between 2D cultures and native tumors 
necessitate conducting these studies with more relevant in vitro 
tumor models to ensure reliability of resulting data.
Limitations of 2D culture systems for chemical compounds 
library screening and drug discovery also contribute to well-
documented inefficiencies in identifying compounds that trans-
late successfully to clinical oncology.[7] For example, several 
promising drug candidates developed for aggressive pancreatic, 
brain, and lung cancers based on success in initial screening 
with standard cell assays ultimately failed clinically.[8] Despite 
significant time and resource investment to develop new cancer 
drugs, currently up to 95% of candidate drugs effective in pre-
clinical tests fail in clinical trials.[9,10] This low productivity 
significantly increases costs of cancer drug discovery to ≈$2B 
for a single drug.[11–13] More widespread utilization of in vitro 
models that more closely model actual human tumors will help 
identify safe and effective compounds, reducing costs and time 
invested in compounds that fail later in drug development.
The need for better in vitro cancer models has fueled intense 
research both in academia and industry, leading to development 
of 3D models as major tools both for basic cancer research and 
drug discovery applications.[14] These models are generated 
using different sets of technologies and offer various degrees of 
complexity including self-assembled and freestanding spherical 
aggregates of cancer cells as cellular spheroids, tumorspheres, 
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organotypic spheroids, matrix-mediated assembled cellular 
aggregates, multilayered cultures of cancer cells or tumor 
slices, organoids, and microfluidics- and microfabricated-
mediated cultures of cancer cells.[15–21] Importantly, inclusion 
of various stromal cells (such as carcinoma-associated fibro-
blasts, immune cells, and vascular cells), addition of matrices 
of generic or defined compositions, modulation of mechanical 
and biochemical properties of the stroma, and generation of 
physiologic levels of fluid flow have all been demonstrated in a 
broad range of studies. We will focus this Progress Report only 
on two popular 3D tumor modeling approaches based on sphe-
roids and organoids developed using natural or synthetic bio-
materials. We highlight and discuss studies that demonstrate 
using 3D models and reproducing key biologic properties of 
tumors. In addition, we provide perspectives on the utility of 
biomaterials-based approaches to tumor modeling and discuss 
areas of need and potential opportunities that can be addressed 
with these models.
2. Biomaterials-Based 3D Cancer Models
Advances in materials science and engineering have led to 
development and use of synthetic and natural materials in 
tissue engineering for a variety of applications, including the 
rapidly growing area of engineering 3D models of cancer.[22–25]  
These materials are used to construct scaffolds of defined 
mechanical and/or biochemical properties to physically sup-
port cell adhesion and growth and facilitate self-assembly of 
cells into 3D clusters (Figure 1). Tissue-engineered models 
of cancer also enable cellular interactions with specific 
biochemical factors conjugated to scaffolds, homotypic inter-
actions of cancer cells, and signaling among cancer cells, 
stromal cells, and matrix proteins. Natural materials such 
as collagen, laminin-rich extracellular matrix (lrECM), hya-
luronic acid (HA), alginate, and chitosan have been used 
alone or in a variety of combinations to provide biomimetic 
supportive structures for cancer and stromal cells and allow 
the cells to remodel the matrix. However, natural matrix pro-
teins are subject to certain limitations, such as batch-to-batch 
compositional variations and changes in crosslinking and 
assembly density, tissue sources from which materials are 
derived, and the expense to derive and purify them. On the 
other hand, synthetic materials such as polyethylene glycol 
(PEG), poly(lactic-co-glycolic) acid (PLGA), and polycaprolac-
tone (PCL) can be conveniently engineered with defined prop-
erties such as stiffness, porosity, and presentation of specific 
signaling molecules present in tumor microenvironments. 
The ability to engineer and control these properties provides 
novel approaches to elucidate effects of defined mechanical 
and biochemical cues on cancer cells. We will present the 
use of a variety of both natural and synthetic materials used 
to construct 3D cancer models; discuss how these in vitro 
models help recapitulate certain properties of native tumors; 
and present how these models advance understanding of 
tumor biology and facilitate testing for new cancer therapies. 
Table S1 in the Supporting Information provides a summary 
of some of these studies in terms of type of biomaterials, 
cancer cells, and major outcomes.
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3. Spheroid Models
Cancer cell spheroids, also known as multicellular spheroids, 
are the simplest in vitro model of solid tumors. Spheroids are 
generated due to the inherent property of epithelial cancer 
cells to form intercellular adhesions and self-assemble into a 
compact aggregate on a nonadherent surface or within a 3D 
matrix. Spheroids of different sizes ranging from few tens of 
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micrometers to a millimeter scale can conveniently be made. 
The 3D morphology of spheroids mimics avascular tumors in 
terms of close cell–cell and cell–ECM adhesions, exposure of 
cells within a spheroid to nonuniform concentrations of soluble 
factors, low oxygen tension in the core of a spheroid resulting 
in hypoxic, slow cycling, and dormant cells, and an acidic extra-
cellular environment. These properties are implicated in a wide 
range of biological processes in cancer as highlighted with the 
following examples: loss of cell–cell contacts through downreg-
ulation of cadherin junctions and catenins allows detachment 
of cancer cells from a tumor mass, enabling transition of the 
cells to a migratory, mesenchymal-like state to facilitate metas-
tasis;[26,27] cancer cell–ECM signaling mediated by adhesion 
complexes promotes cell proliferation and survival;[28] dynamic 
cell–ECM adhesion and detachment through integrins leads to 
traction forces connecting the matrix to actomyosin filaments 
to facilitate cancer cell migration;[29,30] a hypoxic tumor environ-
ment promotes evolution of cancer stem cells with the ability to 
repopulate a tumor mass and resist drug treatments;[31,32] and 
low pH in the acidic extracellular environment reduces uptake 
of weakly basic drugs, such as doxorubicin, conferring resist-
ance to chemotherapy.[33] Additionally, spheroids offer flexibility 
of incorporating different stromal components to accommo-
date studies on how physical interactions between cancer cells 
and tumor stroma and intercellular signaling regulate tumor 
growth, angiogenesis, invasion, and drug resistance. Therefore, 
despite being a relatively simple model, spheroids are inher-
ently suited for a broad range of tumor biological studies.
Due to these advantageous features of spheroids, there has 
been a major push to incorporate spheroids as surrogate tumor 
models in cancer drug discovery. Original platforms for 3D 
cell cultures were cumbersome, expensive, and not amenable 
to high throughput screening operations that are critical to 
the workflow in the pharmaceutical industry. However, recent 
technological developments generate large numbers of consist-
ently-sized spheroids in standard microplates compatible with 
standard robotic instruments such as liquid handlers, high con-
tent imagers, and plate readers. These capabilities simplify and 
expedite formation and drug treatment of spheroids, as well 
as analysis of cellular responses to chemical compounds.[34–37] 
Importantly, several commercially available biochemical assays 
originally developed for 2D cultures, such as PrestoBlue and 
CellTiter Glo, have been optimized for 3D cultures to provide 
quantitative, end-point measures of drug effects on cancer 
cells.[38,39] Collectively, these advances help streamline the use 




Collagen is an abundant structural protein in the body and 
serves as a major substrate for cell adhesion. Collagen is also 
the main matrix protein of desmoplastic tumors of pancreas, 
breast, lung, colorectal, and skin. Cancer cells binding to the 
integrin-binding motif Arg-Gly-Asp of collagen fibrils is medi-
ated by α1β1 and α2β1 integrins.[40,41] Adhesion of cancer cells 
to collagen facilitates multiple key processes including cell 
proliferation, survival, migration, and invasion.[42–44] Consid-
ering the importance of collagen in biology of tumors, various 
Adv. Healthcare Mater. 2018, 7, 1700980
Figure 1. Biomaterial-based spheroid and organoid modeling. A) Approaches to develop 3D tumor models from immortalized cell lines as spheroids 
and biopsies as organoids. Various natural and synthetic materials offer unique advantages to facilitate self-assembly or directed assembly of cells into 
these models. B) Representative images of spheroids and organoids formed using cells of different cancers. Images in (B) were reproduced with per-
mission.[74] Copyright 2010, Elsevier.[92] Copyright 2014, Elsevier.[101] Copyright 2016, Wiley,[163] Copyright 2015, Nature Publishing Group.[165] Copyright 
2017, Nature Publishing Group.[158] Copyright 2014, Elsevier.[157] Copyright 2014, Nature Publishing Group.
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collagen-based 3D cancer models have been developed to study 
these events. These models primarily use dispersed single cells 
or spheroids of cancer cells in a collagen matrix, as well as 
cocultures of cancer cells with stromal cells such as fibroblasts, 
endothelial cells, and adipose derived cells. Collagen used for 
in vitro studies is often derived from bovine skin, rat tail, and 
human placenta.
Cancer cells cultured in a 3D collagen scaffold showed mor-
phological and gene expression similarities to tumors. MCF-7 
breast cancer cells cultured alone in collagen showed elongated 
mesenchymal-like morphology, upregulation of transcription 
factors SLUG, SNAIL, ZEB1/2, TWIST1/2, LEF1 involved 
in epithelial–mesenchymal transition (EMT) of cancer cells, 
and concurrent downregulation of the epithelial cell marker 
E-cadherin and gain of vimentin, β-catenin, and osteonectin 
expression.[45] Collagen protected migrating HT1080 sarcoma 
cancer cells against doxorubicin by modulating cell motility 
proteins focal adhesion kinase (FAK), RhoA, and β1-integrin. 
Doxorubicin at a nontoxic concentration inhibited migra-
tion of HT1080 cells cultured in 2D by 70% and significantly 
decreased FAK, RhoA, and β1-integrin levels. However, cells 
cultured in a 3D collagen matrix showed significant resist-
ance against doxorubicin-mediated inhibition of migration by 
maintaining activity of cell motility proteins, resulting in only 
8% inhibition of migration. This finding was supported by a 
study that demonstrated the genes involved in focal adhesion 
pathway were upregulated in tumor cells by doxorubicin treat-
ment of breast cancer patients.[46] Biomechanical properties 
of collagen also influence cancer cell functions. For example, 
spheroids of MDA-MB-231 breast cancer cells cultured in col-
lagen matrices showed stiffness dependent apoptosis and 
migration.[47] Increasing the matrix stiffness from 0.3, to 
1.2, and to 6.0 kPa resulted in greater resistance to paclitaxel 
treatment. Additionally, increasing the matrix stiffness to 1.2 
and 6.0 kPa caused a reduction of over 20% and 50% in cells 
invading the collagen matrix. This finding was consistent with 
data from ex vivo measurements of bulk modulus of freshly 
excised tumors from a mouse model of breast cancer.[48] Tests 
showed a significant direct correlation between collagen con-
tent of each tumor and its bulk modulus. Stiffer tumors were 
associated with less frequent, smaller local recurrences and 
less extensive metastases.
Dynamic interactions among cancer cells, stromal cells, 
and the extracellular matrix in tumors regulate morphology, 
proliferation, motility, and drug responses of cancer cells. 3D 
models that facilitate tumor-stromal interactions provide a 
unique tool to understand tumor biology. Coculturing breast 
cancer cells with stromal fibroblasts in 3D collagen matrices 
restored the epithelial phenotype of cancer cells. When MCF7 
cells were cultured with normal mammary fibroblasts in a col-
lagen matrix, they formed tight clusters with a distinct border 
and showed apical–basal polarity with a lumen. By comparison, 
monocultured MCF7 cells in collagen formed loose clusters 
without polarity or lumen.[49] A similar finding was reported 
with cocultures of LS174T colon cancer spheroids and normal 
colon fibroblast (NCF) cells in a 3D collagen matrix.[50] Cancer 
cells displayed well organized glandular epithelial structures 
and established desmosomes, adherence junctions, and tight 
luminal junctions, whereas monocultures of LS174T spheroids 
only showed rudimentary desmosomes (Figure 2A,B). Cocul-
ture LS174T-NCF spheroids showed close intercellular con-
tacts with staining of NCF cells for fibroblast activation protein 
(FAP). Collagen fibers showed contraction in the presence of 
NCF cells, which nested around the epithelial cells as observed 
in the human colon adenocarcinoma. Cocultures with NCF 
cells reduced mitotic potential of LS174T cells and enhanced 
Adv. Healthcare Mater. 2018, 7, 1700980
Figure 2. Collagen-based modeling of cancers. A,B) Monocultured LS174T cells only show rudimentary desmosomes, whereas coculture of LS174T 
with NCF results in established desmosomes, adherence junctions, and tight luminal junction. C,D) Invasion of LS174T cells from the spheroid into 
the collagen matrix in the coculture model. E) Schematic representation of a six-layered rollable collagen-cell composite to develop physiologic oxygen 
concentrations. F) Induction of hypoxia due to decreasing oxygen levels into the core of the model and upregulation of hypoxic genes. A–D) Reproduced 
with permission.[50] Copyright 2011, Elsevier. E,F) Reproduced with permission.[54] Copyright 2016, Nature Publishing Group.
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effectiveness of a PI3K inhibitor, LY294002, to induce apoptosis 
in cancer cells and reduce the volume of the spheroids. Impor-
tantly, coculturing LS174T cell spheroids with cancer-associated 
fibroblasts (CAFs) derived from colon adenocarcinoma pro-
moted cancer cell invasion into the collagen matrix (Figure 2C). 
Confocal imaging revealed invasion of LS174T into the collagen 
gel both as single cells and collectively in areas with high CAFs 
density (Figure 2D). Spheroids of LS174T cells alone in collagen 
retained a compact morphology and did not invade the matrix.
A consequence of fibroblast-mediated collagen contraction 
is reduced diffusion of nutrients and oxygen to the spheroid 
embedded in a collagen matrix. This may result in hypoxia and 
necrosis in the central zone of a spheroid and reduced prolif-
erative capacity of cancer cells.[51,52] Both limited proliferation 
of cancer cells and diffusive transport may reduce effective-
ness of chemotherapeutics. For example, coculture spheroids 
of HepG2 liver cancer cells and NIH 3T3 normal fibroblasts 
embedded in a collagen matrix were highly resistant to doxoru-
bicin treatment than freestanding spheroids.[53]
Reduced oxygen diffusion to spheroids of HT-29 cancer cells 
in a dense collagen hydrogel was observed through positive 
staining of cells for pimonidazole during a 2 week culture.[51] 
Hypoxia led to production of VEGF by HT-29 cells and release 
into the matrix. Earlier and higher levels of VEGF production 
resulted when 3T3 fibroblasts or endothelial cells were incor-
porated in the model. This indicated a major role for signaling 
between stromal and cancer cells to promote angiogenesis. A 
similar finding was reported with cultures of MDA-MB-231 
breast cancer cells in type I collagen hydrogels that showed a 
significant upregulation of HIF-1α and VEGF-A within 3 d of 
culture.[40] Decreasing cancer cell density to 25% of the initial 
tests delayed the upregulation of both markers by 2–4 d due 
to reduced competition for available oxygen. Decreasing the 
hydrogel thickness by 50% mitigated diffusion limitations 
of oxygen and nutrients and changes in expression of both 
markers remained insignificant.
A novel model to study hypoxia-mediated changes in cell 
metabolism was developed using a complex rollable composite 
design known as TRACER.[54] A suspension of breast cancer 
cells in type I collagen was loaded onto a ≈35 µm thick cellulose 
scaffold strip, which was sufficiently thin for free access of cells 
to oxygen and nutrients. Rolling the composite onto an oxygen 
permeable metallic core gave a six-layered configuration to 
generate the length scale over which oxygen gradients develop 
in tumors (Figure 2E). When placed in culture media, oxygen 
and nutrients diffusion to cells progressively reduced moving 
from the outer to inner layers, mimicking oxygen gradients in 
tumors at progressively increasing distances from nearby blood 
capillaries. Importantly, the 3D spatial locations of cells in the 
model were mapped to their positions along the unrolled strip 
to facilitate collection and characterization of populations of 
cells from different layers. Those cells located in the middle 
layers (2–4) were under mild hypoxia and showed upregulation 
of the HIF-1α regulated gene, carbonic anhydrase 9, whereas 
cells in the inner layers (4–6) were under severe hypoxia (O2 
< 0.1%) within 6 h and showed upregulation of the HIF-1α 
target gene, REDD1 (Figure 2F). Interestingly, a slight increase 
in oxygen concentration in layers deep in the construct was 
observed at 12 h, indicating an adaptive hypoxia response and 
reduced oxygen consumption by cells. This 3D model helped 
identify various known and unknown mediators of metabolic 
adaptation of cancer cells to hypoxia.
Highlight: Use of collagen for 3D tumor modeling in these 
studies reproduced a wide range of events critical for tumor 
progression: EMT of cancer cells; migration and invasion into 
the collagen matrix; effects of matrix stiffness; drug resistance; 
tumor-stromal interactions; metabolic adaptations to hypoxia; 
and angiogenesis. Understanding biological mechanisms 
underlying these events will facilitate discovery and develop-
ment of new, molecularly targeted drugs to improve cancer 
therapy.
3.1.2. Laminin-Rich Extracellular Matrix (lrECM)
lrECM is a solubilized extract derived from Engelbreth–Holm–
Swarm mouse sarcoma cells. Laminin is an essential compo-
nent of the basement membrane (BM) for polarized epithelial 
morphogenesis. 3D lrECM preserves cancer tissue architecture 
and biology by restoring their biochemical and biomechanical 
properties.[55] Interestingly, malignant subtypes of cancer cells 
can be distinguished from their nonmalignant counterparts 
based on their distinct morphological differences in 3D lrECM 
cultures. These distinct morphologies are also reflected in gene 
expression of the cells and correlate with drug responses in 
vivo. 3D lrECM promotes integrin-mediated signaling between 
cancer cells and ECM proteins such as laminin and fibronectin 
that drive cancer cell malignancy in vivo. As such, 3D lrECM 
provides a valuable tool to identify integrin targets in cancer 
cells.
Nonmalignant breast and prostate cancer subtypes cultured 
in 3D lrECM displayed distinct, polarized, growth arrested, 
acinus like structures, while malignant cancer subtypes formed 
disorganized, proliferative, and nonpolar colonies.[56–58] Malig-
nant breast and prostate cancer cells displayed four distinct 
morphologies in 3D lrECM based on their close cell–cell con-
tacts and invasive potentials: round, mass, grape-like, and stel-
late (Figure 3).[57] Gene expression patterns of breast and pros-
tate cancer cells with similar morphologies frequently clustered 
together, suggesting that the gene expression pattern strongly 
correlates with colony morphology in the 3D lrECM cultures. 
In another study, colorectal cancer cells cultured in 3D lrECM 
scaffolds gained round, mass, and stellate morphologies.[59] 
DLD-1, CaCO2, HT-29, SW-480 cells exhibited solid tumor 
formation capacity, whereas LOVO, COLO-205, COLO-206F 
formed grape-like structures. Regardless of morphology, cells 
showed reduced responses to epidermal growth factor receptor 
(EGFR) inhibition in 3D lrECM compared to 2D cultures. Lewis 
lung carcinoma cells (LLC1) cultured in 3D lrECM formed 
clusters and showed significant cytoskeleton rearrangement 
without stress fibers. Relative to a 2D culture, LLC1 cells in 3D 
lrECM exhibited marked differences in expression of micro-
RNAs, metabolic pathways, MAP kinase pathway, cell adhesion, 
and immune response genes. Comparison of expression levels 
of selected genes and miRNAs between LLC1 cells grown as 3D 
cultures and LLC1 tumors implanted in mouse indicated close 
correlation between the two model systems.[60] Nonmalignant 
human mammary epithelial (HMEC) cultured in 3D lrECM 
Adv. Healthcare Mater. 2018, 7, 1700980
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showed downregulation of 22 genes during cells growth arrest 
and acini formation. These 22 genes were used as signatures 
to predict the prognosis of breast cancer patients in three large 
independent breast cancer microarray datasets. This gene sig-
nature based on 3D lrECM cultures accurately predicted breast 
cancer outcomes in estrogen receptor positive (ER+) and nega-
tive (ER−) tumors.[61]
Interactions of ECM proteins with integrin receptors of 
cancer cells modulate different functions of cancer cells. lrECM 
induces production of high levels of endogenous fibronectin in 
cancer cells. Fibronectin interacts with integrin α5β1 on cancer 
cells through its Arg-Gly-Asp and Pro-His-Ser-Arg-Asn synergy 
sequences. This interaction promotes proliferation, survival, 
and invasion of cancer cells.[62–64] The level of endogenous 
fibronectin secreted by malignant T4-2 breast cancer cells was 
9.4-fold higher than nonmalignant S1 cells, even though both 
sublines originated from the same parental cells. Inhibition of 
integrin α5β1 induced apoptosis in T4-2 cells by suppressing 
AKT signaling.[65] Treatment with a peptide that disrupts 
interactions of α5β1 integrin with fibronectin promoted apop-
tosis and enhanced the effect of radiation treatment on malig-
nant cells (T-42 and MDA-MB-231). This was consistent with 
a study of gene expression data from breast cancer patients 
that revealed an association of high levels of α5-integrin with 
decreased survival.[65] A different study showed that the micro-
environment provided by 3D lrECM promotes preferential 
enrichment of α5β1 integrin and endogenous fibronectin in 
breast cancer cell lines of the basal subtype as compared with 
luminal cells. Blocking β1-integrin in a panel of breast cancer 
cells (T4-2, MDA-MB-231, BT-474, MCF-7, and SKBR3) cultured 
as preformed 3D clusters successfully inhibited growth of these 
malignant cells.[66] Reducing α6- and β-integrins or vimentin 
levels reverted metastatic prostate cancer cells into a nonma-
lignant type and reduced tumor growth in vivo.[67] Further-
more, reversion of malignant T4-2 breast cancer cells to non-
malignant cells by inhibiting β1-integrin significantly reduced 
malignancy in vivo.[68] Inhibiting β1-integrin in HER2-amplified 
breast cancer cells (AU565, SKBR3, and HCC1569) significantly 
increased sensitivity of the cells to the HER2-targeting agents 
trastuzumab, pertuzumab, and lapatinib.[69] In a more complex 
3D coculture model of PC3 prostate cancer cells with HS5 bone 
stromal cells, α6- and/or β1-integrin expression in cancer cells 
increased compared to monoculture of PC3 cells.[70]
Highlight: Using lrECM for tumor modeling distinguished 
malignant from nonmalignant cells based on their 3D mor-
phologies and gene expression profiles; maintained close cor-
relations of expression of selected genes and miRNAs between 
3D cultures and tumors implanted in mice; accurately predicted 
outcomes in specific subtypes of breast cancer; and revealed 
the therapeutic value of targeting specific integrins in cancer 
cells to block signaling driven by ECM proteins, rendering 
metastatic cancer cells non-malignant, promoting apoptosis 
of cancer cells, reducing tumor burden in vivo, and enhancing 
drug responses of cancer cells.
3.1.3. Alginate, Chitosan, Hyaluronic Acid, and Their Combinations
Alginate: Alginate is a family of naturally occurring polysaccha-
rides extracted from brown seaweeds. It supports attachment 
and integration of cancer cells and promotes their growth. 
EpCAM-positive hepatocellular carcinoma cells cultured in an 
Adv. Healthcare Mater. 2018, 7, 1700980
Figure 3. Laminin-rich ECM modeling of breast cancer. Breast cancer cells cultured in lrECM show four distinct morphologies that can be used 
to distinguish malignant and nonmalignant cells. Reproduced with permission.[57] Published under the terms of the CC-BY 4.0 license 2007, 
copyrighted by the authors.
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alginate matrix formed 3D clusters that recapitulated major 
features of glandular epithelium in vivo, such as acini, apical 
morphogenesis, and expression of stem cell-associated proteins 
with β-catenin signaling.[71] Using an alginate-based 3D model, 
the study identified that Wnt/β-catenin signaling pathway acti-
vation was essential for maintaining the hepatocellular car-
cinoma stemness, formation of spheroids, and maintaining 
acinous structures. EpCAM-positive cells cultured in the 3D 
matrix and treated with TGF-β showed EMT signaling, high 
tumorigenic activity, and resistance to doxorubicin and 5-fluo-
rouracil in mouse models compared with cancer cells harvested 
from the same treatment in 2D cultures and used in animal 
tests.
Alginate lacks major integrin-binding sites and does not 
interact with integrins on cancer cells. However, alginate can 
be functionalized with an RGD (Arg-Gly-Asp) peptide sequence 
present in major ECM proteins, such as fibronectin, to allow 
ECM interactions and signaling. Constructing a 3D tumor 
angiogenesis model using RGD-conjugated alginate disks con-
taining dispersed OSCC-3 oral cancer cells showed an increase 
in a proangiogenic marker, IL-8, due to cell–ECM interactions 
and independent of oxygen levels.[72] However, cell–ECM inter-
actions only moderately altered secretion of VEGF. Increased 
proangiogenic molecules promoted invasion of endothelial cells 
into the matrix. Alginate microcapsules were also used to con-
fine cancer cells and facilitate spontaneous formation of sphe-
roids reproducing solid tumor properties. SMMC-7721 human 
hepatocarcinoma cells encapsulated in alginate-poly-l-lysine-
alginate (APA) microcapsules of 200–300 µm diameter showed 
actin reorganization into networks to direct cells to form tumor-
like clusters (Figure 4A). Glucose consumption and lactate 
production of cells correlated well with the cellular prolifera-
tion kinetics. Cells in spheroids were arranged into trabecular 
structures morphologically similar to hepatocarcinoma in vivo 
(Figure 4B). Cells expressed tight junctions, showed microvilli 
on their surface, and developed canaliculi-like structures essen-
tial for the integrity of tissues in vivo (Figure 4C).[73] A similar 
approach was used to encapsulate PC3 human prostate cancer 
cells in a miniaturized aqueous liquid core of microcapsules 
with an alginate hydrogel shell to form 3D cellular aggregates. 
This strategy effectively enriched expression of cancer stem cell 
genes NANOG, OCT4, CD44, and CD133 (Figure 4D).[74] It was 
suggested that this enrichment was due to retention of auto-
crine factors of cells in close proximity when cells were encap-
sulated in the microcapsules. Harvesting the PC3 aggregates 
and implanting them in mouse resulted in significantly larger 
tumors than when disperse PC3 cells or aggregates formed by 
liquid overlay cultures were injected. This was potentially due 
to the enhanced content of cancer stem cells in aggregates 
harvested from the core–shell microcapsules that mimic the 
structure of early embryos, the native home of totipotent–pluri-
potent stem cells.[75–77]
Chitosan: Chitosan is a linear polysaccharide obtained from 
partial deacetylation of chitins of crustaceans. It shares struc-
tural similarities with glycosaminoglycans present in native 
ECM. In contrast to alginate (an anionic polymer), chitosan is 
a cationic polymer. It provides functional amino groups and 
surface charge to promote cell attachment.[78] Colon cancer 
and hepatocellular carcinoma cells cultured on chitosan 
membranes showed increased cell motility, drug resistance, 
self-renewal capacity, and cancer stem cell-like gene expres-
sion. Cancer stem cell genes OCT4, NANOG, CD133, CD44, 
Adv. Healthcare Mater. 2018, 7, 1700980
Figure 4. Alginate microcapsules to model hepatocellular carcinoma. A) Liver cancer cells contained in alginate microcapsule and form spheroids. 
B) Cells show actin reorganization and arrange into trabecular structures, C) express tight junctions and microvilli on their surface, and developed 
canaliculi-like structures. D) Prostate cancer spheroids encapsulated in the alginate core–shell microcapsule display cancer stem cell marker genes 
CD44 and CD133. A–C) Reproduced with permission.[73] D) Reproduced with permission.[74] Copyright 2014, Elsevier.
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and the epithelial maker EpCAM were highly upregulated in 
these cancer cells. Culturing cells on chitosan membranes led 
to activation of canonical Wnt/β-catenin-CD44 signaling in 
CD44+ colon cancer cells and noncanonical Wnt-STAT3 sign-
aling in CD44− hepatocellular carcinoma cells.[79] Compared to 
2D cultures, MCF-7 cells cultured in 3D scaffolds of chitosan, 
derived from prawn chitin, produced more lactate from glu-
cose, showed 35% slower growth with 1 × 10−9 m tamoxifen 
treatment, and required higher tamoxifen concentrations to 
show a comparable toxicity. Decreased activity of tamoxifen 
with 3D cultures in the chitosan matrix was mediated by the 
reduced uptake of an autocrine growth factor in breast cancer 
cells, cathepsin D.[80] Interestingly, chitosan was used as a 
targeting moiety on nanoparticles to eliminate CD44+ breast 
cancer cells.[81]
Chitosan–Alginate: A composite matrix of chitosan and 
alginate provides superior cell adhesion properties. A chi-
tosan–alginate (CA) natural scaffold was synthesized by 
lyophilizing and crosslinking a mixture of chitosan and algi-
nate (Figure 5A,B).[82] The resulting CA scaffold promoted 
enhanced attachment, integration, and proliferation of osteo-
blasts compared to a scaffold purely made of chitosan. Hepa-
tocarcinoma cells in CA scaffolds showed slower proliferation 
than in 2D and Matrigel cultures.[83] Glypican-3, a histochem-
ical marker that is used to distinguish hepatocarcinoma from 
benign hepatocellular mass lesions,[84] increased by 5.5 folds 
in HepG2 cells in CA scaffolds compared to 2D culture. Hepa-
tocarcinoma cells in a CA scaffold were more tumorigenic in 
animal models. Tumors generated from CA precultured hepa-
tocarcinoma cells were nearly twice as large than those gener-
ated using cells harvested from 2D or Matrigel cultures. Addi-
tionally, tumors from CA precultured cells upregulated levels 
of proangiogenic growth factors IL-8, bFGF, and VEGF, and 
induced formation of large, well-rounded blood vessels with 
well-defined endothelial lining (retained features of normal 
blood vessels). Similar results were observed with cultures of 
U-87 MG brain cancer cells in CA scaffolds. Compared to 2D 
cultures, cells in CA showed slower growth, secreted higher 
levels of ECM proteins including fibronectin and laminin, 
exhibited a more rounded and interconnected morphology 
similar to tumor cells in vivo, and upregulated VEGF and 
MMP-2.[85] When CA precultured U-87 MG glioblastoma cells 
were implanted in mice, they facilitated significantly higher 
recruitment of CD31+ endothelial cells than tumors seeded 
with U-87 MG cells harvested from 2D or Matrigel cultures, 
indicating improved ability for angiogenesis. In another study, 
U-87 MG and U-118 MG cells cultured in CA scaffolds showed 
enrichment for cancer stem cells (Figure 5C–F).[86] Various 
stem cell related genes including Nestin, GFAP, frizzled 4, 
GLI, HES, CD44, and CD133 were upregulated in the glioblas-
toma cells. CD44 induced overexpression of EMT transcrip-
tion factors SNAIL1, SNAIL2, and Twist2. CD133+ cells from 
CA cultures formed tumors in mice, while cells lacking this 
marker failed to induce tumors. Chitosan and alginate were 
used to form a nanoscale matrix around T cells for codelivery 
with bone marrow cells to treat leukemia in a mouse model. 
This chitosan–alginate matrix reduced the side effect of graft-
versus-host disease without compromising the antileukemia 
capacity of T cells.[87]
Hyaluronic Acid: Hyaluronic acid is a natural anionic polymer 
and a rich ECM component often overexpressed in tumors. Its 
accumulation around tumors correlates with enhanced inva-
sion of cancer cells, cancer cell malignancy, and poor patient 
outcomes.[88,89] HA interacts with cell surface receptors (e.g., 
CD44 and RHAMM) and HA-binding proteins to mediate pro-
cesses such as cell adhesion, migration, and proliferation.[90] 
The significance of HA in cancer and the ease of its produc-
tion and chemical modification make it an attractive biomate-
rial for cancer research. Nanoparticles were decorated with HA 
for gene and drug delivery to target cancer stem cells.[91–93] HA 
scaffold hydrogels were successfully used to culture prostate 
cancer PDX cells that remained viable with continued expres-
sion of the androgen receptor, resisted docetaxel treatment in 
a 0–1 µM concentration range, but did not show significant 
growth in the HA hydrogels.[94] Unmodified HA hydrogels do 
not support integrin-mediated cell engagement. A strategy to 
overcome this problem is to chemically conjugate cell adhe-
sive RGD peptides to the HA matrix. A biomimetic hydrogel 
Adv. Healthcare Mater. 2018, 7, 1700980
Figure 5. Chitosan–alginate composite scaffolds to model cancer. 
A–B) SEM images of CA scaffold synthesized by lyophilizing and 
crosslinking a mixture of chitosan and alginate. C) Growth and mor-
phology of glioblastoma cells in CA scaffolds compared to monolayer 
culture of cells. D–F) Unlike in monolayer cultures, cells in 3D cul-
ture in the CA scaffolds express high levels of cancer stem cell marker 
CD133. A,B) Reproduced with permission.[82] Copyright 2005, Elsevier. 
C,F) Reproduced with permission.[86] Copyright 2014, Elsevier.
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was constructed by mixing thiolated HA and acrylated copol-
ymer carrying multiple copies of cell adhesive cysteine con-
taining peptide (PolyRGD-AC).[95] LNCaP prostate cancer cells 
encapsulated in HA-PolyRGD as dispersed single cells formed 
multicellular spheroids that expressed higher mRNA levels of 
E-cadherin, α5-integrin, and β1-integrin compared to cells in a 
negative control PolyRDG gels (Figure 6A,B).
Bone is the most common site of prostate cancer metastasis. 
Cocultures of prostate cancer and bone cells in HA hydrogels 
mimic the bone microenvironment of prostate cancer metas-
tasis. HA was specifically modified with integrin-binding pep-
tides GRGDS and crosslinked matrix MMP-degradable peptides 
to enable coculturing MDA PCa 118b prostate cancer PDX cells 
with MC 3T3-E1 osteoblastic precursor cells (Figure 6C,D).[96] 
The coculture increased transcript levels of osteoblast-enriched 
markers osteocalcin, bone sialoprotein, and alkaline phos-
phatase in MC 3T3-E1 osteoblastic cells, indicating the 3D HA 
hydrogel model helped retain the inherent ability of the PDX 
cells to induce bone formation (Figure 6E). The study identified 
that crosstalk between PDX and osteoblastic cells in the hydrogel 
was mediated by autocrine signaling through fibroblast growth 
factor receptor 1 (FGFR1) on the PDX cells. Similarly, these 
receptors were highly expressed by MDA PCa 118b cells in vivo 
(Figure 6F). This indicated that the coculture model reliably 
recapitulated in vivo properties of prostate cancer-bone metas-
tasis. Inhibition of FGFR1 using dovitinib decreased interac-
tions of PDX-derived prostate cancer cells and osteoblastic cells. 
This inhibition reduced cellularity of cocultures and increased 
osteogenic activity of MC 3T3-E1 cells. This was consistent with 
a clinical study where dovitinib showed efficacy in patients with 
advanced metastatic castrate-resistant prostate cancer and bone 
metastasis by reducing lesion size and intensity on bone scans, 
lymph node size, and tumor specific symptoms without propor-
tional declines in prostate-specific antigen (PSA).[97]
HA hydrogels are attractive substrates for binding various 
cytokines. A cytokine releasing HA-based bilayer hydrogel 
system was constructed to allow sustained release of a heparin-
binding epidermal growth factor-like growth factor from the 
heparin decorated hydrogel particle in the top layer into the 
bottom layer containing LNCaP prostate cancer cells.[98] This 
bioengineered growth factor signaling in the HA hydrogel 
allowed formation of large spheroids that showed close cell–cell 
contacts, cortically organized F-actin, and increased protein and 
mRNA expression of proangiogenic factors VEGEF165 and IL-8.
Chitosan-Hyaluronan: Chitosan-hyaluronan (CH) is formed 
by grafting the amine group of chitosan with the carboxyl group 
of HA to form a stable covalent bond. A549 and H1299 small 
cell lung cancer cells cultured in CH scaffolds formed compact 
Adv. Healthcare Mater. 2018, 7, 1700980
Figure 6. Functionalized hyaluronic acid (HA) to model prostate cancer. A,B) Higher mRNA levels of E-cadherin, α5-integrin, and β1-integrin in HA-
PolyRGD compared to the PolyRGD control. C,D) Modification and crosslinking of HA with GRGDS and MMP-degradable peptides to coculture pros-
tate PDX cells with osteoblast cells, to E) enable bone forming capability of PDX and F) preserve in vivo expression of FGFR1. A,B) Reproduced with 
permission.[95] Copyright 2016, American Chemical Society. C,F) Reproduced with permission.[96] Copyright 2016, Elsevier.
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spheroids and displayed slower proliferation compared to the 
2D cultures of cells.[99] Furthermore, cells in spheroids showed 
strong upregulation of N-cadherin, vimentin, and fibronectin. 
Similarly, antiapoptotic genes such as BCRC5 and BCL2, EMT-
related transcription factor TWIST1, and cancer stem cell genes 
CD44, CD133, SOX2, NANOG, POU5F1 were significantly 
upregulated in spheroids formed in CH scaffolds. Glioblastoma 
(GBM6) cultured in CH scaffold showed enhanced stem cell 
marker expression resisted treatment of alkylating agents.[100]
3.1.4. Silk
Silk is a natural polymer and widely used clinically as sutures. 
It is composed of fibroin, a filament core protein, and a glue-
like coating of sericin proteins.[101,102] Oxygen and water per-
meability, slow degradability, cell adhesiveness, relatively low 
thrombogenicity, and amenability to convenient surface modifi-
cation make silk an attractive biomaterial for tissue engineering 
applications including tumor modeling.[103] Osteosarcoma cells 
cultured in 3D silk scaffolds proliferated slower than the cells 
in 2D cultures, and showed similar levels of proliferation maker 
genes such as Cyclin B, E2F1, Ki67, and PcNA as observed 
in a SCID mouse model.[104] Immunocytochemistry showed 
increased levels of proangiogenic markers HIF-1α, VEGF-A, 
and VEGF receptor in cancer cells comparable to the native 
tissue in mouse xenografts. In 3D scaffolds made using fibroin 
from the silk gland of the tropical silkworm Antheraea mylitta 
(Figure 7), growth of MDA-MB-231 breast cancer cells cultured 
for 60 d followed the Gompertz law, similar to the growth of 
avascular solid tumors.[105] Cell proliferation in the construct 
showed spatial variations and a larger number of proliferating 
cells localized toward the periphery of the scaffold. There was a 
marked increase in levels of proangiogenic markers VEGF and 
IL-8 receptors in the cancer cells that was suppressed by com-
bination treatments of paclitaxel with either celecoxib (a COX-2 
inhibitor) or ZD6474 (a VEGFR2 inhibitor). Interestingly, the 
source from which the silk fibroin is derived to construct the 3D 
silk scaffold influences proliferation, viability, and meta bolism 
of cancer cells. Silk derived from A. mylitta provided superior 
cell adhesion and improved viability and proliferation com-
pared to that from B. mori. Similarly, glycolysis of MDA-MB-231 
cells in silk scaffolds of A. mylitta-derived fibronin was similar 
to that in vivo.[106]
Heterotypic cultures of cancer and stromal cells in silk scaf-
folds are also used to study tumor-stromal interactions such as 
breast cancer-bone metastasis and evaluate efficacy of targeted 
therapies.[107] Folate receptors are highly expressed in various 
cancer cells and are attractive drug targets.[108] Nanoparticles 
of silk fibroin, derived from A. mylitta, were used to conjugate 
folic acid and loaded with doxorubicin, to target breast cancer-
bone metastasis in a coculture model of osteoblasts (MG63) and 
MDA-MB-231 human breast cancer cells. This targeted delivery 
through folate receptors on cancer cells decreased the population 
of cancer cells, and the invasiveness and angiogenic capabilities 
of the cells in terms of VEGF secretion particularly. Interestingly, 
there was minimal effect on the proliferation and function of 
bone cells, indicating increased specificity of the treatment 
toward the cancer cells while protecting normal bone cells.
Highlight: The above studies utilized matrices made of algi-
nate, chitosan, hyaluronic acid, silk, or combinations of these 
materials and demonstrated the ability to reproduce key prop-
erties of tumors in vivo. These included arrangement into 
structures morphologically similar to native tumors; slower cell 
proliferation compared to 2D cultures but similar to tumors in 
mouse models; glucose consumption and lactate production by 
cancer cells; production of angiogenic molecules by cancer cells 
including HIF-1α, IL-8, and VEGF to promote recruitment of 
endothelial cells, consistent with mouse xenografts; enrichment 
of cancer stem cells; and activation of stem cell signaling path-
ways. Additionally, harvesting cancer cells from 3D cultures in 
these matrices and implanting them in mice enhanced tumor 
formation and drug resistance relative to cells from 2D cul-
tures. Thus, the 3D environment of these matrices maintained 
malignant properties of cancer cells much more effectively than 
standard 2D cultures.
3.2. Synthetic Materials
3.2.1. Polyethylene Glycol and Its Modified/Functionalized Forms
A major benefit of using PEG to create cell-based tissue engi-
neered constructs is liquid-to-solid transition to form hydrogels 
Adv. Healthcare Mater. 2018, 7, 1700980
Figure 7. Stepwise process of 3D silk fibroin generation from tropical silkworm A. mylitta used to model breast cancer. Silkworms were dissected to 
extract silk glands. Fibroin was isolated from the glands and dialyzed to obtain silk fibroin solutions. The solution was used to fabricate scaffolds and 
films. Reproduced with permission.[105]
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containing cells. Although PEG in its native form is biologically 
inert and compatible with cell culture, its unique chemistry 
allows modifying or conjugating it with natural or synthetic 
bioactive molecules. This design strategy enables interactions 
of PEG with cancer cells to facilitate formation of 3D cultures. 
In addition to simple PEG-based hydrogels for culturing cancer 
cells, hybrid materials using PEG and synthetic or natural mate-
rials are also utilized for specific applications. For example, nat-
ural materials such as hyaluronic acid found in certain tumors 
may be used to better mimic tumor microenvironments. In 
addition, the use of PEG and dextran (DEX) in highly aqueous, 
immiscible polymeric solutions allows a scaffold-free approach 
to form monoculture and coculture spheroids. Below is a sum-
mary of studies using PEG-based materials for 3D cancer cell 
cultures.
PEG Hydrogels: PEG hydrogels were synthesized from pep-
tide functionalized multiarm PEG macromolecules using enzy-
matic reactions.[109] The flexibility of PEG chemistry allowed 
functionalization of the hydrogels with RGD peptides to facili-
tate engagement of the matrix with integrins on cancer cells, 
and MMP-sensitive peptides to allow cell-secreted MMPs 
degrade the hydrogels. OV-MZ-6 and SKOV-3 ovarian epithe-
lial cancer cells embedded in the synthesized hydrogels formed 
compact spheroids and secreted ECM proteins. Proliferation of 
cells, and size and number of spheroids in the hydrogel were 
dependent on the integrin-binding capacity of the hydrogels 
and significantly enhanced with inclusion of RGD peptides. 
Ovarian cancer cell spheroids showed resistance to paclitaxel 
treatment, which correlated with a significant upregulation of 
several integrins (α3, α5, β1) and MMP-9 levels.
A composite hydrogel was synthesized by covalent attach-
ment of fibrinogen fragments to PEG diacrylate (PEG-DA).[110] 
A Michael-type addition reaction was used to form the ester 
bond between the free thiols in the fibrinogen cysteines and 
acrylate end groups on the PEG-DA (PEGylation). The fibrin-
ogen backbone in the PEG hydrogels presented cell adhesion 
motifs and allowed proteolytic degradation by cells. PEG-
fibrinogen precursors were used to synthesize microspheres of 
adjustable stiffness and porosity for 3D culture of breast cancer 
cells MCF-7, SK-BR-3, and MDA-MB-231.[111] Cancer cells 
premixed with the PEG-fibrinogen polymer precursor were 
suspended on a polydimethylsiloxane substrate and photo-
crosslinked to form cancer cell-containing hydrogel micro-
spheres. Hydrogels degraded over time and cells proliferated. 
Unlike MCF-7 and SK-BR-3 cells that formed compact sphe-
roids in hydrogels of different Young’s moduli, MDA-MB-231 
cells showed an elongated morphology in soft hydrogels but 
assumed a round morphology in hydrogels of ≈10 kPa stiffness. 
Cancer cell-containing PEG-fibrinogen hydrogels were also 
made by suspending cancer cells in a PEG-fibrinogen prepol-
ymer solution, adding it to an oil phase to form cell-containing 
aqueous drops, and photo-crosslinking to form microspheres. 
Microspheres were then retrieved and maintained in culture 
media.[112] Different breast and prostate cancer cells were cul-
tured as spheroids for several weeks in microspheres. This 
approach resulted in a large number of spheroids, albeit with a 
wide range of size distributions, due to the size heterogeneity of 
the aqueous drops formed in the oil phase. Nevertheless, sphe-
roids in the PEG-fibrinogen microspheres displayed hallmarks 
of malignant cancer cells such as significant loss of apico-basal 
polarity, cellular and nuclear atypia, increased disorganization, 
elevated nuclear cytoplasmic ratio and nuclear volume density, 
and reduced length of cell–cell junctions.
A redox responsive PEG hydrogel was also reported for gen-
eration and recovery of cancer cell spheroids.[113] A cysteine 
(reducing agent) responsive PEG hydrogel was synthesized 
from octa-thiolated PEG derivative (8-arm PEG SH), horseradish 
peroxidase, and small phenolic compound (glycyl-l-tyrosine). 
HepG2 hepatocarcinoma cells premixed with this precursor 
solution formed hydrogels containing cells that proliferated 
to form spheroids. Addition of a cysteine solution recovered 
HepG2 spheroids that produced significantly higher albumin 
and urea compared to the cells cultured in monolayer. Albumin 
secretion from the HepG2 spheroids was at 37–61 µg/106 cells 
per day, in close agreement with the secretion rate of ≈61 µg/106 
cells per day from hepatocytes in the body.
Hyaluronic acid–PEG: A 384-microplat format, multilay-
ered, 3D coculture system was engineered using aqueous 
solutions of thiolated HA and thiol reactive PEG diacrylate 
(HA–PEGDA).[114] This composite formed a cushion layer pre-
venting cellular interactions with the plate surface and overlaid 
with a layer of cancer cells, such as a bone metastatic prostate 
cancer cells and uterine cancer cells, suspended in HA–PEGDA. 
Both cancer cells proliferated and formed compact spheroids. A 
more complex model was also developed by including stromal 
cells, such ESS1 endometrial stromal sarcoma cells or HS27A 
bone marrow stroma cells, in HA-collagen and overlaying the 
suspension on the layer containing cancer cells. In cocultures, 
spheroids of both cells showed their native phenotypes. Cells 
in prostate cancer spheroids expressed PSA and EGFR, and 
the uterine cancer cells expressed mucin 1 and an estrogen-
induced gene 121 protein. Morphologically, stromal cells in the 
coculture model formed small aggregates rather than showing 
an elongated shape typical of fibroblast cells. Coculture with 
cancer cells also led to both cytoplasmic and nuclear of expres-
sion HDAC2, in contrast to its nuclear localization in mono-
cultures. It was also shown that stromal cells poorly adhered 
to cancer cells, indicating that communication between cancer 
and stromal cells is mediated by paracrine signaling. The utility 
of the model was demonstrated for high throughput screening 
of 232 chemical compounds that generated data reflecting the 
performance of the drugs in vivo.
The utility of thiolated hyaluronic acid (HA-SH) and PEG-DA 
to form HA-SH/PEG-DA hydrogels was shown by culturing 
patient-derived prostate cancer cells.[94] The tumoroids cul-
tured in the hydrogels retained close cell–cell contacts and the 
epithelial phenotype of the native tumors. Androgen receptor 
was mainly localized in the nucleus of the MDA PCa 183 cells 
(androgen dependent prostate carcinoma) in tumoroids com-
pared to MDA PCa118b cells (androgen-receptor negative 
castrate-resistant prostate carcinoma), consistent with in vivo 
models. Primary cells in 3D hydrogel cultures were resistant to 
a chemotherapy drug, docetaxel, compared to spheroids gener-
ated form a bone metastatic prostate cancer cell line (C4-2B) 
that showed dose–response to the drug.
Highlight: These studies benefited from the flexible chemi-
stry of PEG to either functionalize PEG hydrogels with ligands 
for integrins on cancer cells or create composite PEG-based 
Adv. Healthcare Mater. 2018, 7, 1700980
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hydrogels. Morphology of 3D cultures of metastatic cancer 
cells in PEG-based hydrogels depended on matrix stiffness. 
Cancer cells, including primary patient-derived cells, in these 
hydrogels formed spheroid cultures that displayed hallmarks of 
malignant cancer cells, such as significant loss of polarity and 
organization, elevated nuclear cytoplasmic ratio and nuclear 
volume density, expression of tumor-specific antigens, gain of 
tissue-specific functions such as protein secretion at physio-
logic levels, and resistance to chemotherapy drugs.
3.2.2. Polyethylene glycol–dextran aqueous two-phase systems (ATPS)
Aqueous solutions of PEG and DEX above certain concentrations 
result in two immiscible, highly aqueous phases (Figure 8A).[115] 
PEG–DEX ATPS provide a mild environment for various cells, 
including cancer cells, and have been widely used for cell and 
biomolecule micropatterning applications.[116–121] The PEG–
DEX ATPS was used to develop a scaffold-free approach to con-
veniently generate spheroid cultures of cancer cells. The denser 
aqueous DEX phase solution containing cancer cells was dis-
pensed as a submicroliter drop into a nonadherent microwell 
containing the immersion aqueous PEG phase.[38,122] An ATPS 
was formulated with specific concentrations and molecular 
weights of PEG and DEX to result in an ultralow interfacial 
tension of 0.012 mJ m−2 between the two aqueous phases and 
effectively partition cancer cells to the DEX phase drop.[123] Con-
finement of cancer cells within the nanodrop promoted their 
self-assembly and aggregation into a single spheroid within 24 
h of incubation (Figure 8B). Importantly, the PEG–DEX ATPS 
allows free diffusion of nutrients from the immersion PEG 
phase into the DEX phase drop containing the spheroid and dif-
fusive removal of waste products of cells from the drop phase. 
After formation of spheroids, addition of media reduces concen-
trations of the polymers and reverts the ATPS to a single media 
phase. The trace amounts of PEG and DEX remaining in the 
media do not interfere with cell viability and growth, or diffu-
sion of drug molecules to the spheroid.[38]
This facile technology eliminated major difficulties with 
other spheroid formation techniques, such as formation of 
multiple spheroids in wells, inconsistency of size of sphe-
roids, need for special plates, loss of spheroids during liquid 
handling, and incompatibility with standard liquid handling 
tools and screening instruments.[6] Spheroids of triple negative 
breast cancer cells generated with the ATPS technology repro-
duced major biological properties of solid breast tumors.[124] 
This included growth of spheroids over time, secretion and dep-
osition of major ECM proteins such as collagen I, fibronectin, 
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Figure 8. PEG–DEX ATPS to model different to study tumor biology and conduct drug testing. A) A characteristic phase diagram for PEG–DEX ATPS 
shows the binodal curve and a concentration of phase polymers used to generate a two-phase system. B) Skin cancer cells spheroid formation inside the 
DEX drop immersed in the PEG phase. C) Triple negative breast cancer spheroids secrete endogenous ECM proteins, D) contain actively proliferating 
cells (Ki67+, pink color) distributed in a size-dependent manner, E) displaying size-dependent hypoxia (pimonidazole, pink color), F) show elevation of 
cancer stem cell markers under hypoxia, G) display resistance to doxorubicin under hypoxia (diamonds), and H) become sensitive to doxorubicin by 
combination treatment with a hypoxia prodrug TH-302. A,B) Reproduced with permission.[122] C–H) Reproduced with permission.[124]
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and laminin by cancer cells (Figure 8C), gradients of prolif-
erative cells (Figure 8D), size- and density-dependent hypoxia 
(Figure 8E), expression of cancer stem cell markers (Figure 8F), 
and hypoxia-mediated resistance to doxorubicin and cisplatin 
(Figure 8G). Hypoxia was modeled by varying cellular density. 
Spheroids formed using 1 × 105 MDA-MB-157 cells showed 
significantly higher expression of hypoxia-related genes and 
proteins (HIF-1α and carbonic anhydrase 9), and cancer stem 
cell markers (CD24, CD133, NANOG), than spheroids formed 
using 1.5 × 103 cells that were not hypoxic. Chemotherapy drug 
resistance of hypoxic spheroids was significantly and syner-
gistically reduced by a combination treatment using a hypoxia 
activated prodrug, TH-302, and doxorubicin (Figure 8H). This 
technology has successfully been used to form spheroids of 
various breast, brain, skin, and colon cancer cells. Moreover, 
ATPS works with standard microwell plates for automated gen-
eration, drug treatment, and in situ analysis of spheroids using 
robotic liquid handling tools.[125] The potential of this approach 
for high throughput drug screening was demonstrated by 
single- and dual-agent testing of a collection of anticancer com-
pounds against spheroids of brain, breast, and colon cancer 
cells to identify treatments that effectively induce cytotoxic or 
cytostatic effects.[35,36]
3.2.3. Polycaprolactone
Polycaprolactone can be produced through polycondensation 
of a hydroxycarboxylic acid, 6-hydroxyhexanoic acid, and the 
ring-opening polymerization of a lactone, epsilon-caprolac-
tone.[126] Electrospinning was used to form PCL nanofibers that 
promoted cancer cell infiltration and attachment. Immunohis-
tochemical analysis of TC-71 Ewing sarcoma cell spheroids 
cultured in 3D electrospun PCL scaffolds showed that sphe-
roids preserved major markers (CD99+, keratin– and smooth 
muscle actin) routinely used for diagnosis in patients.[127] 
Compared to cells in 2D cultures, spheroids displayed slower 
growth but significantly upregulated phosphorylation of IGF-
1R, similar to activation of the receptor in xenograft tumors. 
Inhibition of IGF-1R signaling in 3D cultures of TC-71 cells 
in PCL scaffolds using MK-0646 (a humanized IgG1 mono-
clonal antibody) caused expression of c-kit and human epi-
dermal growth factor receptor 2 (HER2/neu), both of which 
are implicated in resistance to IGF-1R-targeted therapy, and 
constitutive phosphorylation of insulin receptor IR-β. For-
mation of hybrid IGF-1R/IR receptor heterodimers has been 
reported as a major mechanism of resistance to IGF-1R tar-
geted therapy.[128] Importantly, data from the 3D models were 
consistent with those from the xenograft tumors of Ewing 
sarcoma cells, which could not be captured with 2D culture 
models.
MCF-7 cells cultured in 3D printed circular PCL scaffolds 
showed enrichment of cancer stem cells.[129] Similarly, using 
composite electrospun PCL/chitosan nanofiber scaffolds to cul-
ture MCF-7 and T47-D breast cancer cells led to enrichment 
of CD44+/CD24− cells highly capable of forming mammos-
pheres.[130] These cells isolated from the scaffold and cultured 
in microplates showed resistance to treatment with docetaxel 
and doxorubicin. Although mechanisms of enrichment of 
breast cancer stem cells were not fully explored, the technique 
enabled enrichment of cancer stem cells for drug discovery 
against these inherently drug-resistant cells.
Prostate cancer most commonly metastasizes to bone, under-
scoring the need to understand tumor growth and response 
to therapy in this environment. A 3D tissue engineered bone 
construct (TEB) was formed by mineralizing human osteoblast 
(hOB) cells in a PCL-tricalcium phosphate (mPCL-TCP) scaf-
folds.[131] Interactions of metastasized prostate cancer cells with 
hOB were studied by culturing PC3 or LNCaP cells in the TEB 
construct. This promoted aggressiveness of prostate cancer cells 
that showed elevated levels of steroidogenic enzymes and PSA, 
a biomarker of prostate cancer progression, in hOB-LNCaP 
coculture relative to LNCaP control only.[132] MMP-9 activity 
in hOB and PC3 coculture was highly upregulated but not in 
the tissue engineered bone construct control groups. Similar 
enhancement of MMP-9 activity was observed in xenografts col-
onized with PC3 cells.[133] Furthermore, incorporating LNCaP 
in PEG hydrogels to avoid direct cellular contacts of LNCaP and 
hOB cells led to the identification of potential paracrine sign-
aling molecules in bone metastasis. Expression of androgen-
regulated genes in prostate cancer spheroids was induced by 
bone cells in coculture, indicating the role of bone derived 
stromal soluble factors in growth of prostate tumors.[134] This 
phenomenon has been described in coculture studies of LNCaP 
and osteoblast-like SaOs2 cells,[135] and upregulation of TGF-β1 
signaling has been implicated in bone metastasis of prostate 
cancer cells.[136]
3.2.4. Poly(lactic-co-glycolic) acid
PLGA is a copolymer of poly lactic acid (PLA) and poly gly-
colic acid. PLGA hydrogels promote adhesion and prolifera-
tion of cancer cells. Highly porous PLGA microspheres were 
synthesized using an oil–water emulsion. The surface of the 
microspheres was amino-lysed and coated with type I col-
lagen to facilitate culturing HO8910 ovarian cancer cells. Cells 
on microspheres proliferated and expressed the epithelial cell 
marker E-cadherin.[137] Collagen-coated porous PLGA scaffolds 
were also used to culture U251 glioblastoma spheroids.[138] 
Compared to 2D or freestanding spheroid cultures of the 
cells, spheroids in PLGA scaffolds showed more glycolysis, 
higher expression of angiogenic factors, and greater resist-
ance to doxorubicin treatment. The U251 cells in PLGA scaf-
folds resisted apoptosis (low caspase activity) by upregulating 
apoptosis-resistance proteins such as survivin and BCL-2. Cells 
also upregulated angiogenic factors VEGF and bFGF.[139] Under 
hypoxia, spheroids showed increased resistance to doxorubicin 
but interestingly, the apoptosis-resistance proteins (survivin and 
BCL-2) were downregulated, indicating that drug resistance of 
hypoxic spheroids was independent of these anti-apoptotic pro-
teins and potentially dependent on pathways that involve VEGF 
and bFGF signaling. A more complex 3D nanofibrous scaffold 
was fabricated by electrospinning a mixture of PLGA, PLA, 
and monopolyethylene glycol, that was designated as 3P.[140] 
Spheroid formation of MCF-7 breast cancer, PC3 prostate 
cancer, B16 melanoma, BG1 ovarian cancer, and LLC1 Lewis 
lung cancer cells was demonstrated. This depended on the 
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surface topography and charge of the 3P scaffolds. Compared 
to 2D culture of cells, spheroids in the 3P scaffolds showed 
upregulated levels of an EMT marker, vimentin, over time, and 
reduced E-cadherin expression. Treating spheroids with a PI3K 
inhibitor, LY294002, and a MAPK inhibitor, U0126, abrogated 
the EMT phenotype and restored E-cadherin expression. The 
3P scaffolds were shown to also facilitate 3D culture formation 
with LLC1 cell suspension collected by fine needle aspirates 
from tumor biopsies of C57BL/6 mice.
In another study, a highly porous poly(lactide-co-glycolide) 
(PLG) matrix was fabricated using a gas foaming-particulate 
leaching process to culture OSCC-3 oral squamous cell car-
cinoma cells.[141] Temporal production of VEGF and IL-8 in 
spheroid cultures in the PLG scaffolds was similar to that 
present in tumor tissues. Tumors formed in xenografts by 
implanting 3D PLG pre-cultured OSCC-3 cells contained 
more blood vessels relative to the density of blood vessels 
in tumors formed by implanting 2D pre-cultured cells. The 
tumors formed from 3D PLG precultured spheroids expressed 
higher α5-integrin receptors that are associated with malig-
nancy of cancer cells.[142] The stroma invaded by tumor cells 
in vivo contained myofibroblasts, which are known to pro-
mote a permissive environment for cancer cell invasion and 
growth.[143] Furthermore, OSCC-3 spheroids in 3D PLG scaf-
folds resisted treatment with a PI3K inhibitor, LY294002, tar-
geting driver PI3K mutations in this oral squamous cell carci-
noma cell line.
3.2.5. Thermo-responsive hydrogels
Temperature responsive biomaterials allow self-assembly of 
hydrogels by a temperature change, encapsulation of cancer 
cells upon incubation in 37 °C and supporting cells to form 
spheroids, and isolation of spheroids after cooling the hydro-
gels to liquefy. For example, a thermoreversible hydrogel poly 
(N-isopropylacrylamide-co-acrylic acid) microgel (PNIPAM-
AA) was constructed for in situ generation and release of 
HepG2 spheroids. PNIPAM-AA exhibited less shrinkage for 
long-term cultures and maintained the scaffold structure. 
HepG2 cells proliferated best in the hydrogel with 1% AA 
in the copolymer.[144] Galactosylated PNIPAM-AA microgels 
enhanced liver-specific functions of HepG2 spheroids in terms 
of albumin secretion and urea synthesis over a 3-week culture 
period.[145]
Highlight: The above studies showed successful use of 
PEG–DEX ATPS, PCL hydrogels, PLGA hydrogels and modi-
fied forms of these hydrogels for spheroid cultures with 
a wide variety of cancer cells. In contrast to 2D cultures, 
spheroids showed slower growth but enhanced activity of 
receptor tyrosine kinases, such as IGF-1R, and resistance to 
corresponding targeted treatments as observed in xenograft 
tumors. Enrichment of cancer stem cells, glycolysis, expres-
sion of angiogenic factors VEGF, bFGF, and IL-8, upregulation 
of apoptosis-resistance proteins such as survivin and BCL-2, 
chemotherapy drug resistance, and stromal cell-mediated 
aggressiveness of metastatic cancer cells are hallmark prop-
erties of tumors reproduced in spheroid cultures with these 
biomaterials.
4. Organoid Models
While tumor spheroid models have been widely applied in 
studies of basic tumor growth, angiogenesis, and drug resist-
ance as discussed above, their clinical value has been hin-
dered by reliance on established cancer cell lines, which fail 
to capture the complexity and functionality of real tumors. 
To overcome this limitation, organoid models that provide a 
more complex and physiologic model than cancer cell lines 
and spheroids have recently been developed. Organoids have 
demonstrated excellent potential for disease modeling,[146] 
drug screening,[147] and tissue engineering for drug testing 
and organ replacement. Known as 3D ex vivo cellular cultures, 
organoids form either through self-organization or directed 
assembly under specific organogenesis cues.[148] Organoids not 
only physically resemble the architecture, cellular organization, 
and composition of the original tissue,[149] they also recapture 
genetic signatures of their in vivo counterparts.[150] As com-
pared with spheroids, organoids contain several cell spatially 
restricted lineages of committed cell types generated from 
either pluripotent stem cells (PSCs) or organ-specific adult 
stem cells.[151] They can be efficiently established and stably 
propagated to model benign and malignant tissues including 
kidney,[152] breast,[153] lung,[154,155] colon,[156,157] prostate,[158] 
stomach,[159] liver,[160] thymus,[161] pancreas,[162,163] brain,[164,165] 
ureter,[152] and lymph.[166]
4.1. Organoids as Disease Models
While research with organoids mainly has focused on tissue 
engineering and regeneration,[148,167] there is also a significant 
clinical need for biomimetic tumor models to bridge the tech-
nological gap between standard 2D cultures, 3D cultures such 
as spheroids, and in vivo models of cancer generated from 
established cell lines. However, compared to the large body of 
work using tumor spheroids, very few studies have attempted 
to engineer spatio-temporally organized organoid models to 
recapitulate complex tumor microenvironments. Recent devel-
opments in human patient-derived organoids have shed light 
on precise disease modeling. Directly generated from patient 
biopsies and resections, tumor organoids (tumoroids) reca-
pitulate patient-specific histological features and physiological 
phenotypes in a very efficient and stable manner, therefore 
showing great potential in drug screening and precision medi-
cine.[158,168] A key advance in organoid culture started from 
intestinal organoids developed by Sato and Clevers, where 
human intestinal stem cells self-assembled into crypt-like struc-
tures in Matrigel.[169] Matrigel encapsulation has since become 
the most commonly used approach for all types of organoid 
cultures. Later, Ootani et al. established a different type of 
organoid culture system. To better mimic intestinal stem cell 
niche, using a collagen gel-based air–liquid interface (ALI) 
method.[170] The ALI method was applied to derive organoids 
from oncogene transgenic mouse gastrointestinal tissues,[157] 
and subsequently human colorectal tissues.[171] The resulting 
patient-derived ALI tumoroids closely recapitulated epithelium 
structures of the original tumor and demonstrated resistance to 
cancer therapies.
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Besides derivation from patient tumor samples, tumor orga-
noids can also be generated from normal tissue using gene 
manipulation technologies.[172–174] Matano and Sato introduced 
five gene mutations, including tumor suppressor genes APC, 
SMAD4, and TP53, as well as the oncogenes KRAS and/or 
PIK3CA, into normal human intestinal organoids. Engineered 
organoids formed tumors following implantation in mice. 
However, compared to organoids derived from chromosome-
unstable human adenomas that formed macrometastatic colo-
nies, the genetically engineered organoids failed to colonize 
in the liver, indicating that ‘driver’ pathway mutations alone 
are not adequate to induce invasive behavior.[172] However, in 
another study, transplanted colon organoids recapitulated not 
only tumor formation but also metastasis in vivo.[175] Orga-
noids either assembled from human patient-derived samples or 
genetically engineered mouse models showed time-dependent 
progression from adenoma to metastasis in vivo. Moreover, this 
study also demonstrated the significant role of dysregulated 
Wnt signaling in progression of disseminated colorectal cancer 
cells. These studies highlight how transplantation of ex vivo 
engineered organoids provides a flexible approach to model all 
stages of colorectal cancer development.
Building on successes with intestinal organoids, investiga-
tors now are applying this culture method to cancer and other 
diseases. For example, 3D prostate tumoroids derived from 
prostate cancer circulating tumor cells provided an alternative, 
efficient approach to investigate intratumor heterogeneity as 
compared to tissue biopsy.[176] Kidney organoids with renal pro-
genitors derived from iPSCs successfully repaired acute kidney 
injury, suggesting the possibility of using organoids in regen-
erative therapy for kidney diseases.[177] Recently, patient-derived 
endometrial organoids were developed and used for endocrine-
based and drug sensitivity testing with high success rates and 
reasonable reproducibility.[147]
4.2. Biomaterials for Organoid Culture
Since organoid formation highly depends on the self-assem-
bling capacity of cells, it is essential to create a microenviron-
ment with required niche factors. Unlike spheroid cultures 
that have employed a variety of materials, natural biomaterials, 
especially animal derived-ECM matrices, such as Matrigel and 
collagen, are the primary materials used for organoid culture.
4.2.1. Matrigel
Matrigel is a BM extract composed of a complex mixture of 
over 1000 proteins. It is well-known as the most BM-like nat-
ural material, with type IV collagen, laminin, and nidogen as 
major components. As the most commonly used material for 
organoid culture, Matrigel ultimately augments the self-assem-
bling capacity of PSCs.[178,179] Since its initial development 
several decades ago, applications of Matrigel far exceed other 
biomaterials due to several major advantages: built-in complex 
distribution of nutrients and protein gradients, ease in han-
dling and fast gelling kinetics, and the ready availability of a 
commercialized product with high quality control. However, 
Matrigel has several notable limitations for tissue engineering. 
First, the inherent compositional variability usually results in 
lack of control over individual specific microenvironmental 
parameters. More importantly, due to the cocktail of growth 
factors in Matrigel, the simultaneous occurrence of signaling 
cascades may confound signal transduction in cells undergoing 
organogenesis, leading to an incomplete understanding of self-
assembly mechanisms.[180] Second, the fast gelling of Matrigel 
does not allow precise control over gelation kinetics, leading to 
uncertain microstructure of the final network.[181] The inability 
to manipulate mechanical properties also limits its applica-
tion in studying mechanotransduction during organogenesis. 
Finally, although Matrigel is a widely supplied commercialized 
product, issues with reproducibility could still arise due to the 
inherently inconsistent composition and batch-to-batch vari-
ability. The lack of consistency can result in problems of genetic 
drift in organoid formation, which is particularly significant if 
investigators subculture and passage organoids.
4.2.2. Other Biomaterials
As described above, most studies of organoids as disease models 
have focused on addition of specific exogenous signaling mol-
ecules to modulate the organoid development, cellular biology, 
and dysfunction. The role of the microenvironment, especially 
mechanical cues such as matrix stiffness and permeability, has 
rarely been taken into consideration. The use of Matrigel or col-
lagen results in imprecise control of the mechanical environ-
ment, further complicating studies of mechanical cues driving 
organoid formation and differentiation. For example, intestinal 
organoid models require a 3D matrix to facilitate complex 
mechanical functions, including contraction needed for peri-
stalsis.[182,183] In order to contract, the mechanical properties 
of the matrix must permit elastic deformation with a defined 
porosity, providing binding sites for cell adhesion and migra-
tion. However, conventional natural materials cannot satisfy 
these requirements because manipulation of stiffness by var-
ying components concentrations or crosslinking usually leads 
to the changes in matrix density as well as in architecture and 
biochemical factors.[181] Therefore, biomaterials with adjust-
able mechanical and biochemical properties are in demand to 
replace Matrigel for organoid culture.
Beck et al. overcame the uncontrollable mechanical proper-
ties of Matrigel by incorporating PEG to build a PEG–Matrigel 
composite hydrogel.[184] The varied ratio of PEGDA and PEG-
monoacrylate changed the extent of crosslinking of the PEG 
network, leading to changes in rigidity (from 50 to 4000 Pa) 
of the matrix with constant concentrations of ECM ligands. 
However, organoids derived from mammary carcinoma did 
not show protrusive migration or local dissemination in PEG–
Matrigel composite hydrogels with varied stiffness. To induce 
cell migration, a second series of materials in which adhesive 
peptides were noncovalently incorporated into the PEG network 
were developed. Although the resultant adhesive PEG–Matrigel 
composite hydrogel induced some dissemination of epithelial 
cells at low rigidity, the limited cell migration observed in this 
study indicates failure to reproduce tumor invasion in vivo, par-
tially due to the unfavorable hydrogel microstructure. Recently 
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DiMarco et al. developed a recombinant engineered ECM con-
taining an elastin-like structural backbone and extensions of 
cell-adhesive RGD peptides to precisely control biomechanical 
and biochemical cues for intestinal organoids. This structure 
enabled independent tuning of matrix stiffness decoupled from 
adhesion to understand the individual effects of matrix biome-
chanical and biochemical forces on intestinal organoids.[185]
5. Perspectives/Outlook
5.1. Advanced Tumor Modeling
Spheroid and organoid models have already accelerated under-
standing of organogenesis. In addition, tumor models using 
spheroids and organoids also offer the potential to improve 
patient-specific precision medicine. A primary limitation of 
current tumoroid models is lack of control over biochemical 
and mechanical signals that are crucial to tumor formation and 
metastasis. For future advanced tumor modeling, we believe 
that addition of spatiotemporal chemical/mechanical gradients 
in the matrix will bridge the gap between ex vivo tumoroids cul-
ture and in vivo tumors. An ability to further sculpt the bio-
physical and biochemical microenvironment will help control 
and dissect intercellular signaling in cancer. With the incor-
poration of functional biomaterials and niche factors, tumor 
modeling will provide a more mechanistic understanding of 
how microenvironmental factors influence tumorigenesis and 
metastasis.
This is highlighted in a recent work from our group that 
developed a tumor model by incorporating multicellular sphe-
roids in a new 3D hybrid hydrogel system composed of collagen 
and alginate.[186] Within this well-defined mechanical microen-
vironment, we showed that human mammary fibroblast (HMF) 
cells facilitated migration of MDA-MB-231 breast cancer cells 
out of spheroids and into the surrounding matrix in a sun-burst 
pattern. Based on these findings, we further designed a model 
using the same gel but containing dissociated cancer cells and 
HMF spheroids. As shown in Figure 9, the spheroid made of 
HMF cells expressing chemokine CXCL12 was embedded in 
the collagen–alginate hydrogel with suspended MDA-MB-231 
cancer cells expressing CXCR4. After 5 d of culture in the 3D 
gel system, cells from the HMF spheroid invaded the gel radi-
ally, while the surrounding cancer cells migrated towards the 
spheroid in the same pattern. In this case, instead of defining 
the path for cancer cells, HMF spheroids attracted cancer cells 
from the matrix through gradients of signaling molecules. 
Migration of both cell types followed the same track with a 
radial orientation, indicating the reorganization of matrix net-
work, and tumor-stromal interactions. This system provides a 
technology to investigate interactions among gradients of sign-
aling molecules, multiple cell types, and ECM remodeling in 
cancer cell migration. By further manipulating this system or 
other similar models, investigators will be able to more pre-
cisely identify mechanisms driving tumor progression and test 
potential therapies to block these steps.
Another important consideration for future models is 
incorporation of tumor vasculature. Angiogenesis, the devel-
opment of new blood vessels in tumors from surrounding 
vessels, provides cancer cells access to nutrients and oxygen 
to support anabolic metabolism and overall tumor growth. 
Incorporating vasculature in advanced tumor models will help 
understand regulation of drug responses of cancer cells and 
develop therapeutics to target angiogenesis. In this progress 
report, we highlighted that signaling between cancer cells and 
ECM in 3D tumor models upregulates major proangiogenic 
factors such as VEGF and IL-8. Although there are several 3D 
coculture models of cancer and endothelial cells, absence of 
geometric and physicochemical guidance results in randomly 
assembled endothelial cells and lack of control of angiogen-
esis. Recently, a bottom-up approach was used to develop an 
advanced 3D vascular tumor model that showed increased 
drug resistance of mammary tumors.[187] Initially, avascular 
microtumors were formed in alginate collagen microcapsules. 
These microtumors were then used as a building block for 
assembling with endothelial cells and stromal cells to create a 
macroscale 3D vascularized tumor. These macroscale tumors 
were then cultured in microfluidic channel allowing perfusion 
of nutrients into the macroscale 3D vascularized tumor and 
removal of waste products. The vascular macroscale tumor 
showed 4.7–139.5 times greater resistance to doxorubicin than 
the avascular mammary tumor model. Such advanced macro-
scale 3D vascular models offer a useful tool for discovery of 
new antiangiogenic drugs and studies of molecular mecha-
nisms of uncontrolled angiogenesis in cancer. We believe that 
further developments of this type of bottom-up approach and 
other bioprinting techniques described in the next section will 
provide greater opportunities for cancer research and drug 
discovery.
5.2. Biomaterials and 3D Printing
Conventional natural hydrogel materials present a major road-
block in building sophisticated tumor models because of limita-
tions to form a well-defined architecture. Biomaterial-based 3D 
printing offers a potential solution and allows a more accurate 
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Figure 9. Collagen-alginate matrix to model breast tumor–stromal inter-
actions. Spheroid of HMF (red) that express the chemokine CXCL12 is 
embedded in a collagen-alginate hydrogel mixed with dissociated triple 
negative breast cancer cells (green) expressing CXCR4 receptor. After 3 d 
of culture, cancer cells oriented and migrate toward the spheroid in a sun-
burst pattern, indicating the binding of CXCR4 to CXCL12 induces cancer 
cell invasion. Images were taken using two-photon microscopy and with 
a 25× objective. A) Maximum intensity over the z-projection view of the 
field. B) 3D reconstruction view of the gel.
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and systematic control to reconstruct the tumor microenviron-
ment.[188,189] Biomaterials have been incorporated into 3D rapid 
prototyping to enable a more modular, controlled approach for 
reproducing intricacies of actual tissues. Bioprinting technology 
makes it possible to precisely position cells of different types 
in relation to each other in a 3D environment using hydrogel-
based bioinks.[190–192] Consequently, bioprinted organoids can 
more closely replicate anatomy and functions of target tissues 
or organs for disease modeling and drug testing. In addition, 
incorporation of drug release and delivery by hydrogel bioinks 
will offer a dynamic model to study biomechanical gradients 
and effects on cell behaviors.[193] We believe that further integra-
tion of spheroids and organoids with 3D bioprinting will con-
tinue to enhance research applications of these models through 
spatiotemporal control of specific microenvironmental cues. 
Using multiple printer heads, cell-laden materials with various 
bioligands or sequestered soluble signaling molecules can be 
engineered to elicit targeted cellular assembly, imitating in vivo 
spatiotemporal dynamics of tissue formation and cancer.
In the last two decades, various bioprinting techniques with 
a variety of bioink materials have emerged. However, most of 
the current 3D bioprinting techniques have only shown simul-
taneous deposition of cell combinations of different types 
encapsulated within bioinks via a layer-by-layer deposition pro-
cess.[188] The resultant bioinspired tissue constructs are still in 
early stages of prototyping and development. Incorporation of 
organoids into bioinks to substitute dissociated cells provides 
a promising solution because it offers a secondary hierarchical 
structure over the self-assembled microstructure of organoids, 
leading to a more complex tissue structures.[194,195] Bioprinting 
of uniluminal vascular spheroids produced elongated struc-
tures, due to the fusion of spheroids in the 3D matrix, that 
resemble segments of intraorgan branched vascular trees.[194] 
For future engineering of large tissue constructs and tumor 
environments, bioprinting with more sophisticated control over 
the fusion of thousands of spheroids will be necessary for auto-
mated production and testing. Spheroid- and organoid-based 
3D bioprinting not only allows multiscale assembly of tissue 
units to complex hierarchical organ systems, it also provides a 
more sophisticated platform for future tumor modeling.
As 3D bioprinting of organoids becomes more sophisti-
cated and follows rational design principles, biomaterials with 
precisely adjustable properties will play a significant role in 
directing this process.[196] Therefore, advanced biomaterials are 
in large demand to accommodate several key features including 
a large parameter space for properties, stability, and capa-
bilities for drug loading and delivery. In this regard, seminal 
studies have begun to optimize commonly used bioinks and 
explore new materials with more specialized, organ-specific 
properties.[197,198] Still, more efforts are needed to fabricate 
novel bioinks that meet both cytocompatibility and mechanical 
strength requirements for 3D bioprinting.
3D bioprinted organ models of kidney, liver, and heart are 
already used for testing and identifying novel drugs. Such 
models also are used to test safety and efficacy of drugs in a 
pharmaceutical setting. Although some pharmaceutical com-
panies have adapted 3D inkjet bioprinters for research applica-
tions, broad utility of bioprinters for drug discovery requires 
greater investments to increase availability of commercialized 
products. Use of 3D bioprinting in pharmaceutical industries 
is limited by various factors. First, bioinks/biomaterials are 
limited. Discovery of novel bioinks is essential to help manu-
facturers standardize and automate bioprinters and bioprinting 
processes. Most methods for bioprinting organs are limited to 
use of scaffold-based biomaterials, and very few studies focus 
on identifying potential scaffold-free biomaterials. A hybrid 
technology that combines scaffold-free and scaffold-based bio-
materials could potentially advance development of bioprinters 
and the bioprinting process. Second, a major limitation of 
bioprinting technology is the difficulty of producing large tis-
sues of clinically relevant size and shapes. Recent approaches 
are limited to small tissues and organ models. Scaling up to 
larger tissues is more challenging due to complexities of archi-
tecture and heterogeneity of native tissues. With existing capa-
bilities, producing large constructs requires prolonged printing. 
Enhanced technological capabilities to expedite the printing 
process are highly desirable. Third, commercialized bioprinters 
are costly, ranging from approximately $150k to $200k, and lack 
versatility. Existing bioprinters are rarely customizable by indi-
vidual users. Most bioprinters are not compatible with available 
bioinks, or are not able to dispense various bioinks simulta-
neously. Bioprinting techniques typically lack full automation 
and require considerable investment of hands-on time to con-
struct 3D tissue constructs. Low spatial resolution of available 
bioprints in terms of accurate placement of bioinks detracts 
from their use for high-throughput screening. Therefore, par-
allel developments of bioinks/biomaterials and technologies for 
bioprinters are essential to scale-up bioprinting of 3D tissues, 
including tumors, and facilitate broader use of bioprinting 
techniques in pharmaceutical industries.
To conclude, in the next decade, we envision that tumor 
modeling using engineered biomaterials will be essential to 
understanding basic mechanisms of cancer and advancing pre-
cision medicine to cure more patients of cancer.
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